Science Daily21h
A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Lexicon’s sotagliflozin shows cardiovascular efficacy in published study
Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...
Science Daily2d
Gene therapy for rare epilepsy shows promise in mice
Recent research takes aim at the a variant in gene SCN1B, which causes a severe form of developmental epileptic encephalopathy.